Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “VACCINATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources
PubMed1999

[Vaccination of ostriches (Struthio camelus, Linnaeus, 1758) against Newcastle disease: evidence for vaccine compatibility and seroconversion after vaccinations using the hemagglutination inhibition and virus neutralization tests].

Newcastle disease (ND) remains to be the worldwide most important infectious disease of poultry. This epizootic is in Germany and many other countries a notifiable disease. Prophylactic vaccination is the major tool for the control of ND in poultry and other birds. Eighty-three ostriches (Struthio camelus) which were kept on farms in Germany were checked for the presence of NDV-specific antibodies. Some of these birds are said to be vaccinated against Newcastle disease. Only some of these ostriches contained antibodies which were measurable in haemagglutination inhibition and virus neutralisation tests. Twenty-three previously unvaccinated ostriches were vaccinated with commercially available vaccines. Both the LaSota live and inactivated oil emulsion vaccines were well tolerated following conjunctival or subcutaneous application, respectively. Neither local nor systemic side reactions were observed. After the vaccinations high antibody titres were detected in hemagglutination inhibition and virus neutralisation tests. A strong correlation between both established methods (r = 0.92; < 0.001) were noted.

Animals↗
PubMed2005

Vaccination markers: designing unique antigens to be added to vaccines to differentiate between natural infection and vaccination.

Some important vaccines, including ones against tuberculosis (Tb) and foot-and-mouth disease (FMD), are not used in many developed countries because there is no simple way to differentiate between vaccine-induced immunity and infection. Eliminating major protein antigens has not succeeded in the cases of Tb, FMD and some other vaccine preparations. Instead of eliminating antigens, novel antigens can be added to vaccines in order to induce a unique immunological response proving that the vaccine has been delivered. Methods for producing such unique antigens are presented and preliminary test results reported. The technique may also be useful for immunologically "branding" animals.

Amino Acid Sequence↗
PubMed1997

Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine.

The effects of concomitant administration of antimalarial drugs, oral polio vaccine, or yellow fever vaccine on the immune response elicited by the Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines were investigated. Healthy adults were immunized with CVD103-HgR alone or combined with Ty21a. Subjects were randomized to simultaneously receive mefloquine, chloroquine or proguanil, or oral polio or yellow fever vaccine. The vibriocidal antibody seroconversion rate was significantly reduced (P = .008) only in the group that received chloroquine with the CVD103-HgR. The geometric mean vibriocidal antibody titer was significantly decreased in the groups that received chloroquine (P = .001) or mefloquine (P = .02) compared with titers in groups that received CVD103-HgR alone. However, similar immunosuppressive effects were not observed in the groups immunized with Ty21a and CVD103-HgR. Only the concomitant administration of proguanil effected a significant (P = .013) decline in the anti-S. typhi lipopolysaccharide antibody response. These results indicate that chloroquine and proguanil should not be simultaneously administered with the CVD103-HgR and Ty21a vaccine strains, respectively.

Administration, Oral↗
PubMedDate not supplied

Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark.

In Denmark a polio vaccination program including both inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine ( OPV ) has been in use since 1968. Three injections of IPV are given when the children are five, six, and 15 months of age. Subsequently, three vaccinations with trivalent OPV are administered at the age of three, four, and five years. The acceptance rate is high-93%-98%-and greater than 95% of the population has antibodies to poliovirus. The geometric mean titer of serum antibodies is much greater than 10 IU for all three types. The epidemiology of poliomyelitis and the background for the development of the present vaccination schedule are reviewed.

Antibodies, Viral↗
PubMed1962

Vaccination against poliomyelitis in Poland with types 1 and 3 attenuated viruses of Koprowski. 1. Virological studies of the vaccine strains and serological studies of the vaccinated population.

Mass vaccination of the juvenile population with live poliovirus vaccine was carried out in Poland in 1959 and 1960. In all, some 7 239 000 children 6 months to 14 years old were given type 1 (CHAT) virus, and nearly 6 818 500 children of the same age-group received type 3 (W-Fox) virus.A serological conversion rate (from <1:4 to >/=1:4) of 91.7% was achieved with type 1 and of 91.0% with type 3-a satisfactory demonstration of the immunogenicity of the strains used. Although type 2 virus was not administered, seroconversion with this type occurred in 65.4%. This may have been caused by antigenic elements common to the three poliovirus types, and previous vaccination with Salk vaccine may also have been a contributory factor.The authors conclude that the mass vaccination described in this paper has created a highly immune population in Poland.

Adolescent↗
PubMed1997

Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.

Severe adverse events were evaluated in a comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Vaccinees received four doses (at three, four-and-a half, six and 15-18 months of age) of either DTP or DTaP vaccine or three doses at three, four-and-a half and 15-18 months of age) of DT vaccine. The analysis included 4,273 DTaP recipients, 4,259 DTP recipients and 1,739 DT vaccinees. Convulsions within three days of vaccination occurred in 1/15,912 doses in DTaP recipients and 1/3,926 doses in DTP vaccinees (p = 0.22). Persistent inconsolable crying was more common in DTP vaccinees (1/113 doses) compared with DTaP (1/497 doses, p < 0.001) and DT (1/359 doses, p < 0.001) recipients. High fever (< or = 40.5 degrees C) was less frequent in DTaP vaccinees (1/16,239 doses) compared with DTP (1/5,359) and DT recipients (1/4,665). One hypotonic-hyporesponsive episode was observed.

Cohort Studies↗